ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Clinical trial NCT04975451 · UNKNOWN
Trial details
- NCT number
- NCT04975451
- Sponsor
- Anqin Zhang
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-01
- Primary completion
- 2024-05-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.